Boehringer Ingelheim to Acquire Trutino Biosciences

Boehringer Ingelheim has signed an option to acquire Trutino Biosciences.

Boehringer Ingelheim announced on June 14, 2022 that it has signed an option to acquire Trutino Biosciences, a San Diego-based biotech company.

Trutino Biosciences is a pre-clinical stage biotech company that focuses on the discovery and development of cytokine therapies to treat immuno-oncology and autoimmune diseases. The acquisition will advance Boehringer Ingelheim’s effort to mobilize a patient’s immune system to fight cancer through cancer cell-directed and immune cell-targeting compounds.

Under the agreement, Boehringer Ingelheim reserves the rights to purchase all shares of Trutino Biosciences once specified program milestones have been achieved within a given timeframe. Trutino will continue to operate as an independent company until that time.

“Boehringer Ingelheim is excited to extend our partnership with Dr. Kim and his outstanding team at Trutino Biosciences. Our existing collaboration has made rapid and impressive progress in a short time frame, and we expect this field to have potential combination benefits with our existing immune-targeting assets,” said Clive R. Wood, PhD, corporate senior vice president and global head of discovery research, Boehringer Ingelheim, in a press release. “The selective activation of specific cytokines localized in the tumor microenvironment holds enormous promise and has the potential to be a key element in fully harnessing the power of the immune system to fight cancer.”

Source: Boehringer Ingelheim